Azaribine. asap~ nmidine analog, blocks the decarboxyla:.e conversion of orotidylic acid to uridine monophosphate with a resultant excretion of accumulated orotic acid and orotidine in the urine. Patients treated with azaribine may develop transitory. severe central nervous system symptoms of depression. lethargy, and ataxia. These side effects are not predictable from o ral dosage, and blood levels of the drug are very difficult to determine. All of our psoriatic patients treated with azaribine excreted large but variable amounts of orotic acid orotidinc in the urine. , pol urine ratios of orotic acid orotidine: creal mine correlated very well with measured 24-hr urine output of orotic acid orotidine.
Triazure (azaribine) the triacetylated oral form of 6-azauridine i:. an effective systemic drug for controlling moderate to &evere psoriasis (1). In a double-blind crossover study [2) conducted by us. the effect of azaribine in 27 patients with psoriasis was evaluated at a dose of 125 mg/kg/day. Clinical response was considered to be good to excellent in 18 out of 21 patients on the drug, whereas 19 of the 20 patients on the plareho showPd no improvement or deterioration of their skin lesions. Toxic side effects include a mild reversible anemia and central nervous system (C SJ symptoms of depression, and lethargy which may progress to ataxia. These symptoms are not predictable from the oral dosage of azaribine administered. Blood and urine levels of azaribine and its breakdown products including 6-azauridine are difficult to measure. requiring the use of complicated chromatographic techniques.
Azaribine IS a nucleos1de structural analog of uridine [3 ). When 6-azauridine was given orally [3) it was poorly absorbed and the small amount that was absorbed was rapidly excreted in the urine, predominantly as 6-azauracil following cleavage of the ribose group. Although 6-azauridine is not believed to pass the blood brain barrier [3], 6-azauracil passes the blood brain barrier easily and is very toxic to the central nervous system [4] [5] [6] . Ln contrast to oral 6-azauridine, repeated oral dosage of azaribine results in sif(Tlificantly prolonged blood level~ of 6-azauridine with minimal formation of 6-azauracil [3. 7).
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• From the D1n,mn of Oermatolo~. 8crit>i>" Cllnac and He:.eareh Foundat inn . La Jolla, and t the Dermatulney Sernce. \ 'eteran• Administration Hospnal. San Diego, C'aliturma The de novo pyrimidine pathway [3, 7, 8) for the conversion of orot1c acid to uridylic acid is reviewed in Figure l. 6-azauridme is converted to the monophosphorylated form, 6-azauridylic acid, by uri dine kinase p ). This derivative competitively inhibits the decarboxylase conversion of o rotidylic acid (OMPJ to uridylic acid, resulting in the accumulation of OMP and orotic acid and a decreased production of RNA [9) and DNA. O M P is excreted in the urine as orotidine. O rotic acid is not detected in normal tissue and on ly 1-2 mg are excreted in the urine daily in a normal subject. Approximately 2.5 mg of orot1dine are excreted in a 24-hr urine [10) . Orotic acid has only two known pathways of metabolism in humans. By a reversa l of reaction!> in Figure I . OMP can be reduced to dihydro-orotic acid and subsequently hydrolyzed to carbamyl aspartate. Most of the orotic acid is converted in the de novo pyrimidine pathway to uridylic acid [II).
The following report describes the procedures used by us for following psoriatic patients on azaribine with urine orotic acid orotidine ( OA 1 OJ/c reatinine ratios as a guideline to prevent C;-JS side effects.
MATF:HIALS AND METHODS

Se/ectwn of Patwnts
Thirty-eight patients with untreated moderate to severe psona~is wPre sPIPcted for study. The patients re(·ein•d no systemic or topical treatment to their skin for one month prwr lilt he "tudy. The patients seleded had no generallted sy~temtc 11lness such as anemia. renal or Ji, er dtsease which would contraindicate use of an antip~rimidine Initial exammation included histof) and physical exammallon, urmalysis, chest x-ray. determma· tiun uf CHC. SGOT, alkalmP pho~phatase . creatinine, and blood sugar Photographs were obtained. Women ol child-lu.>armg age received a pre~nancy te:.t befnre therapy and dunng lrPatment at regular intervals. Most of the "llhJects "ere fnlluwcd ru. oUl-patients.
T HE JOURNAL OF IN\'EST IGATI\ E DEHMATOLQ(;y
Ftt:. I: De novo pynmtdine pathway for the synthesis of undvlit· ot·td from orntie a<·id The decarboxvla~e block by 6-azaundvlic acid 1,., ,ho'"" ·
Plan of Stud\
T he patients were millall) begun on 1:.1.' 1 mg azaribine/ kg/day in lnur equally d1' idcd do~e' taken a lt er meal~ and at bedume The 1>a t 1ent~ ''ere seen weekly and the time ol treatment for each ,·aried from approximntely 4 10 week..., depending on response 10 therap~· . It was poss1ble to obtain I(Ond dmttal results t80 90 per(·ent resolution of psorillllC plaque~) withm 4-10 weeks after begmnmg the rap\ 10 mcl'it patient~ At each dink visit the skm response wos evaluated un a grading 'cale as follo ws: Patients w1th llO \00 percent clearing of the skm were graded ru, excellen t : those with 60 0 pe rcPnt improvem ent as good; 40-60 percent resolution of the lesion s was graded us fa1r : 10 percent improvement to no c hange was graded as no improvement: and progres,.,ion of the di~easc was graded as wnrse. The patients were al~o evalua ted to r the C'NS "ide effPcts of depression. faugue. letharJ0. and atax111. Svmptoms of nausea were also documented.
The patients were told to void a nd discard thetr unnc a t home before <·omtng to the clinic in the a.m. Linne samples were collected ut each visit: l ('C nf u rinl' was sent to the laboratory J(Jr spot urine creatinine determination and 1 cc was fro1en for determmation ofOA • 0 levels.
Oralie Actd ()rnl!dtne Drtermtnatwm
OA · 0 determmatwn ha~ bPen renewed in detail 10 several puhlicatton~ jiO, 121 and we have pre,·iou"l)
shown 121 that OA + 0 ran he measured in t he unne of psonat1c pattenh by a modthc:auon of IU>gen< and Porter's 1121 spectwphotnml't ric method fnr determmmg u rine urollc at·td level" The as"a' a, originally descrihed hy Adachi [I :ll 1s bnelh re' iewed here as it applies to azaribine therapL It 1s hased upon the p rincipal that ornt 1c arid and/or orotidine reac1 with bromine water to form 5. fi' -dihromnbarhll uriC' acid This C'ompound is reduced bv a~corhic acid to barbituric acid. Harbnunc ac1d react!' w1th p-dimethvlaminobenzaldehyde ( Ehrlich 's reagent) fo rmmg a yellow color wh 1ch ha!i a max1mum optical density <it 480 m". Pure OA 0 produt•e an optical dens1tv proportional to concentration. In the unne of an mdtvidual sec reting large amounts of OA • 0. the rnncl'ntrauon of OA • 0 IS high. alltm ing the tN' of wry ~mall mlume;; of urine.
Before ossa\, all precipitated OA -0 was redissolved by warming the bample. and the analysis was <'arried out at room temperature. A .05 ml aliquot was m1xcd with 2.9fi ml ol 0.2 M pma~sium ctl rate buffer. pll 2.fi. A blank was pre pared lmm :1 ml of the buffer. O.!i ml of satura ted bromine water was added to the sample. After l min Ul ml of ;)'"r llRrnrbic acid in the buffer was odded. After 2 min 2 ml ol Vi' • p-dtmethylammobenraldehyde in ~-propanol were added. and after 90 mm the opllt'al denstly at IRO m" wa~ dPtermmed in a Heckm11n sphect m phot nmt'ler. A standard curve was determined for known 'alup,. ol orotic acid added to control urines and the concentra!lon!-. of orotic acid in micrograms/ millilitl'r lor ~pC'cimens under consideration "ere taken from the i . ... taw>n ulthe t) pe ol cun e observed in 6 patients whu had dailv urine ratio" determined for at lea~t 10 davs . Two Jlat i 'Pnts werP hospnahzed and had datly ra t i(>s for I weeks All olthP~e patients showed the initial IH-h r peak standa rd cur.·P. ThP t•nnt•entration of OA t 0 in th e urine sample I I' Will II wa-. dh tded h\· the unne creal inine (mj(/mll resultmg in a ratm !'X t>re~sed a.' ~Jidmg . Azanhine I 1 R m~l. 6 -;uatmdtnl' 1!1 mgl. 6-a1auridylic acid t:l mgl and uridine (:i mgl dtd nut I( I\ l' culor in t h e a~"a'
OA ., 0 expressed as a ratio over creatinine on the sa me spe<·i men correlated well with the amount o f OA ... 0 excreted in the urine in 24 hr. This correlation is shown in Figure 2 .
The dail~ response cu r\'e for excretion of OA t 0 in any mdi\'idual patient on azaribine is shown in Figure : t The subsequent results of the urine OA + 0 determinations in this ~tudy were all from samples taken at least 5 days alter a patient was begun on azaribine therapy. Therefore, the OA + 0 ratios analayzed would not be innuenced by the early 48-hr peak. The results of the OA 0 creatinine ratios for all of our pat tents treated with azaribine are summarized in Tables I, Il, and Figure 4 . In Table I are listed all of the patients, number of weeks on the drug, dosage, ratio range, number of urine OA +-0 creatinine determinattons, the number and value of each ratio over 600, and symptom~. The severe C S symptoms as noted were at the times of the elevated ratios only although the dosage range for both the symptomatic and asymptomatic patient:-. was stmilar. Table II creatinine ratios that ranged between 250 and 600 had minimal to no CNS symptoms with good clearing of their psoriatic plaques. Howe\·er when a patient's OA 1 0 ratio began to go above 600, he would begin to experience marked mental symptoms of depression, fatigue and/ or lethargy. Three patients who had ratios O\·er 600 also had symptoms of nausea and/or emesis. We observed that if the daily dosage of azaribine was lowered by 25 40 percent in a patient who began to develop C. S symptoms. there was a rapid decrease to absence of the CNS symptoms within 24 48 hr and a corresponding drop in the OA "" 0 ratio. Three patients from this group and three from another study who were followed with OA ... 0 ratios below 200 had poor clinical responses . The ratio was also an aid in determinmg whether a patient was actually taking his full prescribed daily dosage of azaribine. A patient who misses doses of the drug will have very low ratios (Table I) . Most of our patients had 80 90 percent resolution of their psoriattc lesions at a dosage level of azarihine that would keep their average ratio between 200 and 600 during the course of treatment. This ratio level corresponded to a dosage range of 3.5-12.5 gm of azaribine per day in our patient group. The average dosage for satisfactory therapy with minimal CNS symptoms was 7.5 gm/ day. Five of our patientR who had very severe depre::.sion and/or ataxia had very high ratios.
VVithout the use of the OA t 0 / creatinme ratio we found it difficult to adjust and monitor the proper dosage of azaribine in treating our psoriatic patients. The ratio was helpful tn determinmg when a patient was at a safe dosage level with regard to preventmg CNS symptoms. COMME!I.TS There ts a rare genetic disorder of pyrtmidine metabolism in humans characterized by retarded growth and development, hypochromic anemia, and excessive urinary excretion of orotic acid 1111.
The anemia is unresponsive to the usual forms of therapy. This genetic disease is known as hereditary orotic aciduria 181 and less than 10 cases have been reported. It represents the only specific ge· netic disorder of pyrimidine nucleotide synthesis so far elucidated in man. Studies of hemic cells, liver homogenates, and fibrobla~ts from these children have demonstrated reduced activities of both orotidylic pyrophosphorylase and orotidylic decarboxylase. These enzymes catalyze the conver::.ion of orotic acid to uridylic acid. Reduced levels or inhibition of these enzymes result in excretion of high le\·els of orotic acid in the unne. Administration of 6-azauridine in man produces a somewhat analogous ~ituation. All of our patients on azaribine ( 125 mg/kg/dayl excreted large amounts (0.2 1.:~ gm) of orotic acid orotidine (OA + Ol in the urine in 2·1 hr.
Azarihine is an effeetive method for controlling severe psoriasts. but while under treatment v. ith this drug mo~t p~oriatic patientl> will experience moderate to . evere CN' symptoms if their daily dosage is too high. From our experience we believe that patients should be sta rt ed on a maximum initial dose of 6 8 gm of azaribine per day. Most patients in our experience do not tolerate a higher initial dosage without symptoms of depression, fatigue. nausea and/or emesis. However, it can be difficult to predict from the calculated daily dosage of azaribine whether or not a patient will develop C S side effects. We have found that the spot unne OA t 0 creatinine ratio is an excellent guide to follow psoriatic patients on azaribine. By following the spot urine ratios we have been able to adjust the dosage of azaribine in our severe psoriatic patien ts in orde r to keep their ratios within a therapeutic ra nge whil e at the same time preventin g them from developing C S side effects.
Azarioine wa~ ktndly ouppliecl hv the Calbwchern Com pan) . San Diego. C'allfnrma.
